PharmaEssentia Corporation (TPE:6446)
Taiwan
· Delayed Price · Currency is TWD | Market Cap | 231.23B |
| Revenue (ttm) | 15.63B |
| Net Income (ttm) | 5.05B |
| Shares Out | 371.16M |
| EPS (ttm) | 13.59 |
| PE Ratio | 45.84 |
| Forward PE | 29.13 |
| Dividend | 1.10 (0.18%) |
| Ex-Dividend Date | n/a |
| Volume | 1,200,516 |
| Average Volume | 1,645,568 |
| Open | 610.00 |
| Previous Close | 606.00 |
| Day's Range | 604.00 - 629.00 |
| 52-Week Range | 428.03 - 780.00 |
| Beta | 0.42 |
| RSI | 44.03 |
| Earnings Date | May 8, 2026 |
About PharmaEssentia
PharmaEssentia Corporation, a biopharmaceutical company engages in medicine discovery, supplements in developing specialty pharmaceutical reagents, API, and new drug patterns developments in the Americas, Europe, Asia, and Taiwan. Its products include BESREMi, an interferon therapy indicated for polycythemia vera, essential thrombocythemia, PMF, and adult T-cell leukemias. The company also develops Ropeg + anti PD-1; PEG-IL-2 (P11838); PEG-Cytokines; PD-1-IL-2v; ADC; ADCS; NY-ESO-1 TCR-T; and Novel TCR-T for the treatment of solid tumor and imm... [Read more]
Financial Performance
In 2025, PharmaEssentia's revenue was 15.63 billion, an increase of 60.61% compared to the previous year's 9.73 billion. Earnings were 5.05 billion, an increase of 70.13%.
Financial StatementsNews
PharmaEssentia Says FDA Accepts SBLA For ET Treatment Ropeginterferon Alfa-2b-njft
(RTTNews) - PharmaEssentia USA Corp., a subsidiary of PharmaEssentia Corp. (6446.TW), on Tuesday said the U.S. Food and Drug Administration has accepted its supplemental Biologics License Application ...
ICC Arbitral Tribunal Rules in Favor of AOP Health in Arbitration Proceedings Pertaining to BESREMi® (Ropeginterferon alfa-2b)
Today, a tribunal under the auspices of the International Chamber of Commerce (ICC) served a partial final award in a dispute between PharmaEssentia Corp. ("PharmaEssentia") and AOP Orphan Pharmaceuti...